Efficacy of intranasal and spray delivery of adjuvanted live vaccine against infectious bronchitis virus in experimentally infected poultry

Deville, S.; Arous, Juliette Ben; Boyer, François; Borisov, Vladimir; Dupuis, Laurent

doi:10.1016/j.provac.2012.04.012

Cited by 19 publications

(14 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The live vaccine virus stimulates more vigorous immune response as they replicate in the host and simulate the natural infection. Adjuvanted live IBV vaccine induced higher immune responses than live vaccine alone [38], supports the concept of present study. Further, the combination of R-848 withinactivated IBV vaccine showed higher antibody response than the vaccine alone group.…”

Section: Discussionsupporting

confidence: 89%

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Matoo

Bashir

Kumar

et al. 2018

Microbial Pathogenesis

View full text Add to dashboard Cite

Adjuvant enhancing mucosal immune response is preferred in controlling many pathogens at the portal of entry. Earlier, we reported that a toll-like-receptor 7 (TLR7) agonist, resiquimod (R-848), stimulated the systemic immunity when adjuvanted with the inactivated Newcastle disease virus vaccine in the chicken. Here, we report the effect of R-848 when adjuvanted with live or inactivated avian infectious bronchitis virus (IBV) vaccines with special emphasis on mucosal immunity. Specific pathogen free (SPF) chicks (n = 60) were equally divided into six groups at two weeks of age and immunized with either inactivated or live IBV vaccine adjuvanted with or without R-848. Groups that received either PBS or R-848 served as control. A booster was given on 14 days post-immunization (dpi). R-848 enhanced the antigen specific humoral and cellular immune responses when co-administered with the vaccines as evidenced by an increase in the antibody titre in ELISA and stimulation index in lymphocyte transformation test (LTT) till 35 dpi and increased proportion of CD4 and CD8 T cells on 21 dpi in the flow cytometry. Interestingly, it potentiated the IgA responses in the tear and intestinal secretions when used with both live and inactivated IBV vaccines. The combination of IBV vaccine with R-848 significantly up-regulated the transforming growth factor beta 4 (TGFβ4) transcripts in the peripheral blood mononuclear cells (PBMCs) than that of the respective vaccine per se. An enhanced secretory IgA response is likely due to the up-regulation of TGFβ4, which is responsible for class switching to IgA. In conclusion, co-administration of R-848 with inactivated or live IBV vaccine enhanced the systemic as well as mucosal immune responses in the chicken.

show abstract

Section: Discussionsupporting

confidence: 89%

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Matoo

Bashir

Kumar

et al. 2018

Microbial Pathogenesis

View full text Add to dashboard Cite

show abstract

“…According to the manufacturer, both adjuvants significantly enhance the strength and duration of the immune response and are suitable for a wide range of infectious agents. Indeed, the ability of both adjuvants to induce specific mucosal immunity against various pathogens in target animals has been assessed [ 33 34 35 ]. In this study, pigs that received the vaccines containing IMS1313 and IMSgel exhibited a strong serum PEDV-specific antibody response.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs

Lee

Yang

Kim

et al. 2018

Clin Exp Vaccine Res

View full text Add to dashboard Cite

PurposeThe first aim of this study was to develop a novel inactivated porcine epidemic diarrhea virus (PEDV) vaccine using the recently isolated Korean PEDV QIAP1401 strain and to evaluate its protective efficacy in growing pigs. The second was to determine the optimum adjuvant formulation of the inactivated PEDV vaccine that induces protection against viral challenge.Materials and MethodsTo generate high titers of infectious PEDV, the QIAP1401 isolate was passaged in Vero cells. The experimental vaccines were prepared from a binary ethyleneimine-inactivated QIAP1401 strain passaged sequentially 70 times (QIAP1401-p70), formulated with four commercial adjuvants, and administered twice intramuscularly to growing pigs. Challenge studies using a virulent homologous strain of PEDV QIAP1401-p11, which was passaged 11 times after isolation, were performed to assess protection against disease progression and viral shedding during the 15-day observation period. The vaccine-induced antibody responses were measured in serum samples collected at predetermined time points by indirect enzyme-linked immunosorbent assay and virus neutralization test.ResultsThe QIAP1401-p70 strain had 42 amino acid (aa) mutations, including a 25 aa deletion, and was selected as the inactivated PEDV vaccine candidate. Although none of the pigs that received the experimental vaccines were completely protected against subsequent viral challenge, they exhibited a significantly higher immune response than did non-vaccinated control pigs. Among the vaccine groups, the highest antibody responses were observed in the pigs that received an oil-based multiphasic water/oil/water (W/O/W) emulsion adjuvanted vaccine, which delayed the onset of clinical symptoms and viral shedding.ConclusionA novel inactivated PEDV vaccine formulated with a W/O/W emulsion adjuvant was both immunogenic and protective against viral challenge.

show abstract

“…In view of the conjunctival route of vaccine administration, we focused on commercial adjuvants such as Montanide Gel01 and chitosan, which according to the manufacturer's recommendations and in some publications [28][29][30][31] can be incorporated into vaccines with a mucosal route of administration.…”

Section: Discussionmentioning

confidence: 99%

Safety of the novel vector vaccine against Brucella abortus based on recombinant influenza viruses expressing Brucella L7/L12 and OMP16 proteins, in cattle

Tabynov¹,

Kydyrbayev²,

Ryskeldinova³

et al. 2014

J Vaccines Immunol

View full text Add to dashboard Cite

Citation: Tabynov K, Kydyrbayev Z, Ryskeldinova S, Yespembetov B, Syrymkyzy N, et al. (2015) eertechz AbstractThis paper presents the results of a study of the safety of new vector vaccine against B. abortus based on recombinant influenza A subtype H5N1 or H1N1 (viral constructs vaccine formulation) viruses expressing Brucella ribosomal protein L7/L12 and Omp16, in cattle. To increase the effectiveness of the vaccine, adjuvants such as Montanide Gel01 or chitosan were included in its composition. Immunization of cattle (5 animals per group) with the viral constructs vaccine formulation only, or its combination with adjuvants Montanide Gel01 or chitosan, were conducted via the conjunctival method using cross prime (influenza virus subtype H5N1) and booster (influenza virus subtype H1N1) vaccination schedules. Vaccine candidates were evaluated in comparison with the positive (B. abortus S19) and negative (PBS) controls. Comprehensive studies involving thermometry and clinical examination, hematology and biochemical blood analysis, showed that all of the viral constructs vaccine formulation, as well as their combination with adjuvants, compared to the commercial bacterial vaccine B. abortus S19 were completely safe in cattle. Furthermore it is shown that the developed vaccines can effectively differentiate vaccinated animals from infected animals. Brucella L7/L12 or Omp16 proteins. The influenza A virus contains a segmented genome consisting of eight negative-strand RNA fragments. Of these, the smallest fragment (NS) -encoding two proteins: viral nonstructural protein (NS1) and nuclear export protein (Nep) -is a convenient target for genetic manipulation as NS1 is able to tolerate foreign sequences exceeding its own length [25]. Thus, the ORF of NS1 was used for inserting Brucella sequences in this study. The А/Puerto Rico/8/34 (H1N1) strain was used as the backbone for obtaining influenza A virus vectors expressing Brucella L7/L12 or Omp16 sequences in the form of fusion proteins with the N-terminal 124 amino acid residues of NS1.Our previous studies have shown that a bivalent vaccine formulation comprising a mixture of recombinant influenza A virus subtype H5N1 or H1N1 expressing the ribosomal L7/L12 or Omp16 proteins in prime and booster immunization mode (via conjunctival injection) in cattle induced a strong antigen-specific T-cell immune response, and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant [24]. Based on this, the next stage of our study was to evaluate the safety of the proposed new live vector vaccine in cattle. Additionally, we evaluated the possibility of differentiating infected animals from vaccinated animals using the developed vaccine.

show abstract

Efficacy of intranasal and spray delivery of adjuvanted live vaccine against infectious bronchitis virus in experimentally infected poultry

Cited by 19 publications

References 22 publications

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken

Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs

Safety of the novel vector vaccine against Brucella abortus based on recombinant influenza viruses expressing Brucella L7/L12 and OMP16 proteins, in cattle

Contact Info

Product

Resources

About